New “Wet” AMD Medication Delivery System

The FDA has approved Roche’s Susvimo (ranibizumab), a long-lasting injectable drug for treating people with “wet” age-related macular degeneration.

Susvimo, which continuously delivers therapy via a refillable ocular implant, can be administered just twice a year, providing an alternative to other injections that are often given monthly.

The drug’s approval was supported by phase 3 data demonstrating that patients treated with Susvimo experienced vision increases equivalent to those receiving monthly ranibizumab injections. Roche noted that 98 percent of patients were able to go six months before needing their first refill of Susvimo.

Additional Information

Roche News Release

Product Video and Important Safety Information

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.